Replimune Group Inc (REPL) - Total Assets
Based on the latest financial reports, Replimune Group Inc (REPL) holds total assets worth $333.59 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Replimune Group Inc to assess how comfortably operating cash covers total debt obligations.
Replimune Group Inc - Total Assets Trend (2017–2025)
This chart illustrates how Replimune Group Inc's total assets have evolved over time, based on quarterly financial data. See REPL total equity for net asset value and shareholders' equity analysis.
Replimune Group Inc - Asset Composition Analysis
Current Asset Composition (March 2025)
Replimune Group Inc's total assets of $333.59 Million consist of 89.9% current assets and 10.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.2% |
| Accounts Receivable | $3.73 Million | 0.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Replimune Group Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see REPL company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Replimune Group Inc's current assets represent 89.9% of total assets in 2025, a decrease from 98.2% in 2017.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2025, down from 90.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.7% of total assets.
Replimune Group Inc Competitors by Total Assets
Key competitors of Replimune Group Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Replimune Group Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.60 | 11.43 | 33.25 |
| Quick Ratio | 5.60 | 11.43 | 33.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $230.27 Million | $499.69 Million | $469.20 Million |
Replimune Group Inc - Advanced Valuation Insights
This section examines the relationship between Replimune Group Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.63 |
| Latest Market Cap to Assets Ratio | 1.38 |
| Asset Growth Rate (YoY) | 13.0% |
| Total Assets | $551.33 Million |
| Market Capitalization | $762.97 Million USD |
Valuation Analysis
Above Book Valuation: The market values Replimune Group Inc's assets above their book value (1.38x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Replimune Group Inc's assets grew by 13.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Replimune Group Inc (2017–2025)
The table below shows the annual total assets of Replimune Group Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $551.33 Million | +13.04% |
| 2024-03-31 | $487.72 Million | -24.57% |
| 2023-03-31 | $646.59 Million | +40.20% |
| 2022-03-31 | $461.19 Million | -15.08% |
| 2021-03-31 | $543.10 Million | +132.00% |
| 2020-03-31 | $234.10 Million | +51.69% |
| 2019-03-31 | $154.33 Million | +136.87% |
| 2018-03-31 | $65.15 Million | +185.51% |
| 2017-03-31 | $22.82 Million | -- |
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP… Read more